R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.
A first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.